Uromonitor:非肌层浸润性膀胱癌患者监测中尿液生物标志物的临床验证与性能评估
本研究纳入439例患者共528次非肌层浸润性膀胱癌监测,所有患者在接受膀胱镜检查前完成标准诊疗方法并留取尿液行Uromonitor检测。Uromonitor检测复发灵敏度87%(95%CI 74-95)、特异度99%(98-100)、阳性预测值93%(82-98)、阴性预测值99%(97-99),在各级别各分期中均保持高性能。
要点
- Uromonitor检测NMIBC复发灵敏度87%(95%CI 74-95),47例复发中仅6例未检出。
- Uromonitor特异度99%(98-100),阳性预测值93%(82-98),阴性预测值99%(97-99)。
- Uromonitor在全部NMIBC级别和分期中灵敏度和特异度等指标均保持高水平。
核心结论
- Uromonitor是接受常规监测患者中检测NMIBC复发的可靠工具,不受分期和级别影响。
- 据作者所知,这是评估Uromonitor性能的最大单中心研究,验证了其在临床实践中的实用性。
研究设计与样本
- 本研究纳入439例患者共528次NMIBC监测。
- 所有患者接受标准诊疗方法,并在膀胱镜检查前留取尿液行Uromonitor分析。
- 以膀胱镜加经尿道膀胱肿瘤电切术组织病理学为金标准,计算复发检测的灵敏度、特异度、阳性预测值和阴性预测值。
主要发现
- Uromonitor灵敏度87%(95%CI 74-95),47例复发中仅6例未检出。
- Uromonitor特异度99%(98-100),阳性预测值93%(82-98),阴性预测值99%(97-99)。
- 膀胱镜显示22例假阳性(32%)未经经尿道膀胱肿瘤电切术确认,而Uromonitor仅3例阳性检测未发现病灶。
- 528次筛查总复发率为8.9%(n=47)。
- Uromonitor在全部NMIBC级别和分期中灵敏度、特异度、阳性预测值和阴性预测值均保持高水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Alternative, noninvasive, cost-effective methods to complement or serve as substitutes to current standard-of-care (SOC) procedures in nonmuscle-invasive bladder cancer (NMIBC) follow-up are needed. Uromonitor is a urine biomarker test detecting bladder cancer recurrence through the screening of TERT, FGFR3, and KRAS hotspot mutations. The aim of this study was to assess Uromonitor performance by comparing it with the current SOC methods. MATERIALS AND METHODS: Four hundred thirty-nine patients with 528 NMIBC surveillances were enrolled in this study. All patients underwent SOC methods and provided a urine sample for Uromonitor analysis before undergoing cystoscopy. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for recurrence and compared with the gold standard cystoscopy plus transurethral resection of bladder tumor histopathology. RESULTS: Uromonitor displayed a sensitivity of 87% (95% CI, 74-95), with only 6 of 47 recurrences failing to be detected; specificity of 99% (98-100); PPV of 93% (82-98); and an NPV of 99% (97-99). Cystoscopy showed a total of 22 false positives (32%) not confirmed by transurethral resection of bladder tumor, whereas Uromonitor presented only 3 positive tests where no lesions were found. Overall recurrence rate was 8.9% (n = 47) among 528 total screenings. Sensitivity, specificity, PPV, and NPV values for Uromonitor remained high across all NMIBC grades and stages. CONCLUSIONS: Uromonitor represents a reliable tool in the detection of NMIBC recurrence in patients undergoing routine surveillance, regardless of stage and grade. To our knowledge, this is the largest single-center study assessing Uromonitor's performance, thus validating its usefulness in clinical practice.
引用
- Ramos P, Brás JP, Dias C, et al. Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer. J Urol. 2024. PMID: 39561374. doi:10.1097/JU.0000000000004335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。